Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Observational 1

Sponsor

Cancer Type

Other 1Lymphoid 1

Conditions

Obesity 1Lymphoma, Follicular 1

Interventions

Cyclophosphamide 12Rituximab 9fludarabine 6Prednisone 5Vinorelbine 4Vincristine 4Epirubicin 4zanubrutinib 3Nivolumab 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Gemcitabine 3Drug Therapy 3pegylated granulocyte colony-stimulating factor 2fludarabine phosphate 2Thiotepa 2Metformin 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Doxorubicin 2Cytarabine 2Bortezomib 2treosulfan 1plerixafor 1pegfilgrastim 1parsaclisib 1obinutuzumab 1nilotinib 1liposomal doxorubicin 1ivarmacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Fluorescence Polarization Immunoassay × Lymphoid × Clear all
NCT06114498 2026-01-23

Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction

National Medical Research Center for Therapy and Preventive Medicine

Active not recruiting
240 enrolled
LymphoidOther

Lymphoma, Follicular, Obesity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡